Impact of Small Tumor Size on Prognosis in T3N1 Colon Cancer.

Background: Traditionally, large tumor size is associated with poor survival in colon cancer, but its impact remains limited and controversial. Recently, the impact of small tumor size on prognosis has gained attention. This study aimed to investigate whether small tumor size can be an additional parameter for T3N1 colon cancer prognosis.

The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.

Background: FOLFIRI (5-FU + leucovorin + irinotecan) plus ramucirumab is one of the standards in second-line metastatic colorectal cancer (CRC) patients progressing after treatment with oxaliplatin/fluoropyrimidine with bevacizumab, but there is no evidence on its efficacy without prior bevacizumab. Moreover, VEGF-D has not been confirmed as a predictive biomarker for ramucirumab's efficacy, either.

Methods: The RAINCLOUD study was a multicenter, single-arm, phase II trial conducted in Japan.

The relationship between intravenous olfactory test and taste disorder in patients with olfactory disorder.

Background: The intravenous olfactory test (alinamin test [AT]) is a retronasal olfactory assessment and may evaluate the flavour disorder; however, studies assessing whether AT accurately determines the severity of taste disorders are lacking. Our study aims to evaluate the relationship between AT and subjective taste disorders in the patiensts with olfactory disorder.

Methods: Between April 2019 and March 2020, 228 patients visited our smell clinic reporting olfactory disorders.

Trends in Olfactory Threshold Test Results and Limits of Olfactory Testing in Patients with Parosmia.

Introduction: Parosmia poses a clinical challenge due to a lack of established testing methods, leading to underestimated self-reported symptoms. This study investigated olfactory threshold trends, aiming to highlight parosmia prevalence, analyze threshold patterns, and assess diagnostic potential in current olfactory testing.

Methods: A total of 407 patients who visited our olfactory clinic from April 2009 to September 2015 were categorized into parosmia and non-parosmia groups based on initial visit questionnaires.

Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.

The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) remains controversial. We report results from a randomized phase 2 DEEPER trial (UMIN000018217, jRCTs061180022) to test the superiority of modified (m)-FOLFOXIRI plus weekly cetuximab over bevacizumab in patients with RAS wild-type (wt) mCRC. Primary endpoint was depth of response (DpR).